Adial Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Adial Pharmaceuticals' CEO is Cary Claiborne, appointed in Aug 2022, has a tenure of 2.25 years. total yearly compensation is $801.62K, comprised of 58.1% salary and 41.9% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $61.41K. The average tenure of the management team and the board of directors is 3.8 years and 7.3 years respectively.
Anahtar bilgiler
Cary Claiborne
İcra Kurulu Başkanı
US$801.6k
Toplam tazminat
CEO maaş yüzdesi | 58.1% |
CEO görev süresi | 2.3yrs |
CEO sahipliği | 0.9% |
Yönetim ortalama görev süresi | 3.8yrs |
Yönetim Kurulu ortalama görev süresi | 7.3yrs |
Son yönetim güncellemeleri
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$12m |
Mar 31 2024 | n/a | n/a | -US$11m |
Dec 31 2023 | US$802k | US$466k | -US$7m |
Sep 30 2023 | n/a | n/a | -US$8m |
Jun 30 2023 | n/a | n/a | -US$9m |
Mar 31 2023 | n/a | n/a | -US$10m |
Dec 31 2022 | US$1m | US$357k | -US$11m |
Sep 30 2022 | n/a | n/a | -US$14m |
Jun 30 2022 | n/a | n/a | -US$16m |
Mar 31 2022 | n/a | n/a | -US$17m |
Dec 31 2021 | US$688k | US$15k | -US$19m |
Tazminat ve Piyasa: Cary's total compensation ($USD801.62K) is about average for companies of similar size in the US market ($USD655.65K).
Tazminat ve Kazançlar: Cary's compensation has been consistent with company performance over the past year.
CEO
Cary Claiborne (63 yo)
2.3yrs
Görev süresi
US$801,621
Tazminat
Mr. Cary John Claiborne, MBA, is the Owner and Chief Executive Officer of Prosperity Capital Management LLC. He serves as an Independent Director at LadRx Corporation (formerly known as CytRx Corporation)...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, President & Director | 2.3yrs | US$801.62k | 0.95% $ 61.4k | |
CFO, Treasurer & Secretary | 7.4yrs | US$389.03k | 0.17% $ 10.7k | |
Chief Legal Officer | 3.8yrs | Veri yok | Veri yok | |
Vice President of Corporate Development | no data | Veri yok | Veri yok | |
Controller | 3.8yrs | Veri yok | Veri yok |
3.8yrs
Ortalama Görev Süresi
Deneyimli Yönetim: ADIL's management team is considered experienced (3.8 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, President & Director | 3yrs | US$801.62k | 0.95% $ 61.4k | |
Chairman & Lead Independent Director | 8.6yrs | US$60.22k | 0.013% $ 829.4 | |
COO & Director | 7.3yrs | US$261.93k | 0.0055% $ 353.3 | |
Independent Director | 10.2yrs | US$56.22k | 0.21% $ 13.7k | |
Independent Director | 10.2yrs | US$53.22k | 0% $ 0 | |
Independent Director | 9.8yrs | US$59.22k | 0% $ 0 | |
Chairperson of Scientific Advisory Board | 6yrs | Veri yok | Veri yok | |
Member of the Scientific Advisory Board | 5.8yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 5.8yrs | Veri yok | Veri yok |
7.3yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ADIL's board of directors are considered experienced (7.3 years average tenure).